PROF. GIRISH SHAH, the recipient of “Outstanding Achievement in Carcinoid/ Neuroendocrine Tumor Research” in 2006 from the Carcinoid Cancer Foundation, Inc. of USA, is a Professor at the Faculty of Medicine at Laval University in Quebec City. He has been chief of the Laboratory for Skin Cancer Research at the CHU de Quebec (CHUL) Hospital Research Centre of Laval University since 1997. Prof. Shah’s research is focused on carcinoid neuroendocrine tumors and solar ultraviolet radiation-induced skin cancers with specific emphasis on DNA damage, DNA repair and cell death processes, all of which can influence either the development of these cancers or their resistance to therapy. Dr. Shah has authored 55 peer-reviewed articles, which have been cited more than 2,387 times in literature. In addition, he has authored 4 book chapters and 119 presentations at the meetings. Dr. Shah’s team, in collaboration with two carcinoid clinicians in Canada and USA, had earlier reported that nearly ¼ of the carcinoid neuroendocrine tumor patients suffer from subclinical niacin (vitamin B3) deficiency, an incidence that is much higher than pellagra, the clinical niacin deficiency syndrome reported in these patients. His recent work has identified how this biochemical anomaly can be exploited to improve efficiency of chemotherapy of carcinoid NET cancers. He is currently also the President of the Scientific & Medical Advisory Board of CNETS Canada.